WEBINAR ON DEMAND
Duration: 1 hour

The rapid growth of complex therapies—such as CAR-T, gene editing, and RNA-based treatments — combined with the challenges of scaling late-stage pipelines, is reshaping the pharmacovigilance (PV) landscape. Organizations must embrace innovative technologies and strategies to address growing data volumes, operational complexities, and evolving regulatory demands while maintaining patient safety.

Viewers will learn how to:

• Streamline adverse event detection and reporting with advanced technologies like AI/ML, natural language processing, and cloud-powered PV systems.
• Eliminate manual inefficiencies in late-stage clinical trials with automation for faster, scalable processing.
• Integrate real-world evidence, patient support data and clinical insights for proactive risk management under a unified safety ecosystem.
• Identify safety signals early using predictive analytics, creating opportunities to devise mitigation strategies.
• Leverage technology-enabled compliance solutions to support conversations with regulators.

SPEAKERS

Mary Coli
Executive Director, PV Operations, Patient Safety & Pharmacovigilance
Takeda
 

Anupam Agarwal
Senior Vice President, Global Head of Drug Safety & PV
Denovo Biopharma
 

Tanmay Desai
Executive Director, Head, Global PV Operations
Kyowa Kirin, Inc.
 

Anu Bhaskaran
NA Markets Lead - Life Sciences Digital Operations
Cognizant